 Tumor Necrosis Factor-alpha
"Tumor Necrosis Factor-alpha" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS.
| Descriptor ID |
D014409
|
| MeSH Number(s) |
D12.644.276.374.500.800 D12.644.276.374.750.626 D12.644.276.972.626 D12.776.124.900 D12.776.395.930 D12.776.467.374.500.800 D12.776.467.374.750.626 D12.776.467.972.626 D23.529.374.500.800 D23.529.374.750.626 D23.529.972.626
|
| Concept/Terms |
Tumor Necrosis Factor-alpha- Tumor Necrosis Factor-alpha
- Tumor Necrosis Factor alpha
- Cachectin-Tumor Necrosis Factor
- Cachectin Tumor Necrosis Factor
- TNFalpha
- TNF-alpha
- Tumor Necrosis Factor
- Tumor Necrosis Factor Ligand Superfamily Member 2
- Cachectin
- TNF Superfamily, Member 2
|
Below are MeSH descriptors whose meaning is more general than "Tumor Necrosis Factor-alpha".
Below are MeSH descriptors whose meaning is more specific than "Tumor Necrosis Factor-alpha".
This graph shows the total number of publications written about "Tumor Necrosis Factor-alpha" by people in this website by year, and whether "Tumor Necrosis Factor-alpha" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1987 | 1 | 0 | 1 | | 1989 | 2 | 1 | 3 | | 1990 | 3 | 0 | 3 | | 1991 | 0 | 5 | 5 | | 1992 | 1 | 0 | 1 | | 1993 | 0 | 1 | 1 | | 1994 | 5 | 3 | 8 | | 1995 | 0 | 4 | 4 | | 1996 | 1 | 11 | 12 | | 1997 | 2 | 8 | 10 | | 1998 | 4 | 5 | 9 | | 1999 | 2 | 6 | 8 | | 2000 | 7 | 6 | 13 | | 2001 | 4 | 9 | 13 | | 2002 | 5 | 14 | 19 | | 2003 | 14 | 11 | 25 | | 2004 | 5 | 26 | 31 | | 2005 | 5 | 13 | 18 | | 2006 | 4 | 14 | 18 | | 2007 | 6 | 17 | 23 | | 2008 | 4 | 22 | 26 | | 2009 | 9 | 12 | 21 | | 2010 | 7 | 9 | 16 | | 2011 | 8 | 12 | 20 | | 2012 | 7 | 9 | 16 | | 2013 | 7 | 7 | 14 | | 2014 | 6 | 14 | 20 | | 2015 | 6 | 10 | 16 | | 2016 | 0 | 6 | 6 | | 2017 | 1 | 2 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Tumor Necrosis Factor-alpha" by people in Profiles.
-
Choi YS, Jung MK, Lee J, Choi SJ, Choi SH, Lee HW, Lee JJ, Kim HJ, Ahn SH, Lee DH, Kim W, Park SH, Huh JR, Kim HP, Park JY, Shin EC. Tumor Necrosis Factor-producing T-regulatory Cells Are Associated With Severe Liver Injury in Patients With Acute Hepatitis A. Gastroenterology. 2018 03; 154(4):1047-1060.
-
Bronckers IMGJ, Seyger MMB, West DP, Lara-Corrales I, Tollefson M, Tom WL, Hogeling M, Belazarian L, Zachariae C, Mahé E, Siegfried E, Philipp S, Szalai Z, Vleugels RA, Holland K, Murphy R, Baselga E, Cordoro K, Lambert J, Alexopoulos A, Mrowietz U, Kievit W, Paller AS. Safety of Systemic Agents for the Treatment of Pediatric Psoriasis. JAMA Dermatol. 2017 Nov 01; 153(11):1147-1157.
-
Solomon DH, Kay J, Duryea J, Lu B, Bolster MB, Yood RA, Han R, Ball S, Coleman C, Lo E, Wohlfahrt A, Sury M, Yin M, Yu Z, Zak A, Gravallese EM. Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial. Arthritis Rheumatol. 2017 Sep; 69(9):1741-1750.
-
Bonaterra GA, Driscoll D, Schwarzbach H, Kinscherf R. Krill Oil-In-Water Emulsion Protects against Lipopolysaccharide-Induced Proinflammatory Activation of Macrophages In Vitro. Mar Drugs. 2017 Mar 15; 15(3).
-
Li Z, Hodgkinson T, Gothard EJ, Boroumand S, Lamb R, Cummins I, Narang P, Sawtell A, Coles J, Leonov G, Reboldi A, Buckley CD, Cupedo T, Siebel C, Bayat A, Coles MC, Ambler CA. Epidermal Notch1 recruits ROR?(+) group 3 innate lymphoid cells to orchestrate normal skin repair. Nat Commun. 2016 Apr 21; 7:11394.
-
Navarro-Millán I, Herrinton LJ, Chen L, Harrold L, Liu L, Curtis JR. Comparative Effectiveness of Etanercept and Adalimumab in Patient Reported Outcomes and Injection-Related Tolerability. PLoS One. 2016; 11(3):e0149781.
-
Matzelle MM, Shaw AT, Baum R, Maeda Y, Li J, Karmakar S, Manning CA, Walsh NC, Rosen V, Gravallese EM. Inflammation in arthritis induces expression of BMP3, an inhibitor of bone formation. Scand J Rheumatol. 2016 Oct; 45(5):379-83.
-
Bhattacharjee S, Zhao Y, Dua P, Rogaev EI, Lukiw WJ. microRNA-34a-Mediated Down-Regulation of the Microglial-Enriched Triggering Receptor and Phagocytosis-Sensor TREM2 in Age-Related Macular Degeneration. PLoS One. 2016; 11(3):e0150211.
-
Deodhar A, Strand V, Kay J, Braun J. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann Rheum Dis. 2016 May; 75(5):791-4.
-
Campi-Azevedo AC, Costa-Pereira C, Antonelli LR, Fonseca CT, Teixeira-Carvalho A, Villela-Rezende G, Santos RA, Batista MA, Campos FM, Pacheco-Porto L, Melo Júnior OA, Hossell DM, Coelho-dos-Reis JG, Peruhype-Magalhães V, Costa-Silva MF, de Oliveira JG, Farias RH, Noronha TG, Lemos JA, von Doellinger Vdos R, Simões M, de Souza MM, Malaquias LC, Persi HR, Pereira JM, Martins JA, Dornelas-Ribeiro M, Vinhas Ade A, Alves TR, Maia Mde L, Freire Mda S, Martins Rde M, Homma A, Romano AP, Domingues CM, Tauil PL, Vasconcelos PF, Rios M, Caldas IR, Camacho LA, Martins-Filho OA. Booster dose after 10 years is recommended following 17DD-YF primary vaccination. Hum Vaccin Immunother. 2016; 12(2):491-502.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|